Monday, October 29, 2007 1:40:55 PM
From slides shown at the Alzheimer's Society's annual event entitled "Competing Paradigms in Alzheimer's Research", specifically a presentation from the Harvard Medical School, this data discusses the APOE genotypes.
Note that in Elan's pivotal trial program, the sub-populations (which amount to different disease indications, as they will have separate trials) are determined by whether or not they carry the 'APOE-e4 allele'.
APOE-e4 is risk factor for late-onset AD
•APOE - AD candidate gene on chromosome 19 - binds Ab in CSF.
•3 APOE variants (prevalence):
-APOE-e2 ~2% - protective (with e3)
-APOE-e3 ~75% - neutral
-APOE-e4 ~20%; >50% in AD - risk
•One e4 allele increases risk >3-fold.
•Two e4 alleles increase risk >10-fold.
•e4 risk strongest between 60-70 yr
How many more AD genes are there?
*Twin studies indicate that at least 80% of AD is inherited.
*The known early-onset familial AD gene mutations in APP, PSEN1, and PSEN2 account for only 1-2% of all AD.
*APOE-e4 acts an inherited risk variant in roughly 50% of late-onset sporadic AD cases.
*APOE-e4 likely requires other inherited risk variants and environmental factors to trigger AD.
*Roughly 70% of AD genetics remains unsolved.
"....on the biotech battle-field, you need some élan...."
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM